Arbuckle Stuart A's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Aug 10, 2022
- Accession no.
- 0000899243-22-028244
- Filed
- Aug 10, 2022
- Trade date
- Aug 9, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.71M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Arbuckle Stuart ACIK 0001557290 | Officer (EVP, COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2022 | Common Stock | MOption exerciseAcquired | +1,926 | $155.57 | +$299,627.82 | 66,686 | Direct | |
| Aug 9, 2022 | Common Stock | SSaleDisposed | −4,790 | $300.53F2,F3 | −$1,439,538.7 | 61,896 | Direct | |
| Aug 9, 2022 | Common Stock | SSaleDisposed | −900 | $301.42F2,F4 | −$271,278 | 60,996 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 9, 2022 | Common Stock | MOption exerciseDisposed | −1,926 | $0.00 | $0 | 6,635 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 2 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $300.53 (range $300.00 to $300.84).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $301.42 (range $301.13 to $301.61).
Referenced by the price of 1 transaction in Table I.